What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

RespiratoryRecon, 1712 Commercial Drive, Naples, FL (2026)

04/27/2026

HFOV Cuts Severe Lung Disease in Premature Newborns

A 32% reduction in severe BPD and no increase in other complications.

Bronchopulmonary dysplasia begins in the NICU and follows premature infants for years. It increases the risk of respiratory rehospitalization, neurodevelopmental delay, and long-term pulmonary morbidity. Every intervention that meaningfully reduces its incidence or severity has consequences that extend far beyond the initial hospital stay.

A randomized clinical trial published in JAMA Network Open in March 2026 evaluated HFOV against CMV in 386 preterm infants, born at or before 34 weeks' gestation and diagnosed with neonatal RDS.

HFOV experienced lower rates of BPD by both clinical definitions used in the study. Using the 2001 definition, the reduction was approximately 8%. Using the more stringent 2019 definition — which more precisely categorizes disease severity — the reduction reached 32%. Both outcomes trended in the same direction. Neither was trivial.

Equally important was the safety profile. No statistically significant differences were found between the two ventilation groups in mortality, severe retinopathy of prematurity, necrotizing enterocolitis, severe intraventricular hemorrhage, air leaks, or patent ductus arteriosus.

The study is single-center, and multicenter replication will strengthen the case for broader adoption. But the signal is clean and the safety data are reassuring.

Takeaway 1 — HFOV reduced BPD in preterm infants with neonatal ARDS.

Takeaway 2 — Death, NEC, IVH, and air leaks were statistically equivalent between groups, supporting safety alongside efficacy.

Reducing incidence & severity of BPD is not simply a unit-level win — it affects pulmonary health, developmental outcomes, and healthcare utilization well into childhood.

Source: Li J, et al. "High-frequency oscillation vs mechanical ventilation for neonatal acute respiratory distress syndrome: a randomized clinical trial." JAMA Netw Open. 2026;9(3):e260268.

04/27/2026

Visuals are often worth a 1,000 words!

This Chest infographic summarizes the immunologic pathways driving severe asthma and highlights biologic drug targets across T2 and non‑T2 inflammation. It links common triggers to epithelial alarmins, downstream cytokines, and cells, then maps corresponding biologics and their mechanisms, concluding with normal versus asthmatic airway remodeling illustrations.

Content adapted from the American College of Chest Physicians infographic “Biologic Management in Severe Asthma for Adults" that was posted last week.

04/25/2026

Roadmap for the Wheezing Toddler

Three or more wheezing episodes before age three — and until now, no standardized playbook for what comes next.

Recurrent wheezing is one of the most common respiratory presentations in infants and toddlers, yet clinicians have long managed it without consistent, evidence-based guidance. That gap has now been formally addressed.

A panel of pediatric respiratory and allergy experts, convened by the Committee of Pediatrics at the China Medical Education Association, published evidence-based clinical guidelines in Pediatric Investigation in March 2026 — the first of their kind for this population.

The guidelines define recurrent wheezing as three or more episodes, each separated by a 7-day asymptomatic window, in children aged 29 days to 3 years. Classification extends beyond simple symptom patterns, accounting for immunological profile, age of onset, and severity — distinctions that directly shape therapeutic decisions.

For those working in pediatric respiratory or primary care, this framework offers something we rarely have with this population — a structured starting point grounded in evidence.

Key Takeaways
* A clear definition now exists: three or more wheezing episodes separated by 7-day asymptomatic intervals in children 29 days to 3 years — giving clinicians a standardized threshold to work from.
* FeNO, pulmonary function testing, and viral and bacterial pathogen identification are strongly recommended in the workup, pushing well beyond clinical assessment alone.
* The cyclical management model — Evaluation → Diagnosis → Treatment → Re-evaluation → Re-diagnosis — reflects the reality that recurrent wheezing is rarely a one-and-done diagnosis.

Source: Committee of Pediatrics., et al. (2026). Evidence-based guideline for clinical practice in the diagnosis, treatment, management, and prevention of recurrent wheezing in infants and toddlers in China. Pediatric Investigation.DOI: 10.1002/ped4.70046

04/24/2026

Sleep Apnea Makes COPD's Muscle Wasting Significantly Worse

Nocturnal oxygen dips may be quietly dismantling your COPD patient's muscles while they sleep.

When we follow patients with COPD over time, we often attribute declining strength and exercise capacity to lung function alone. But a study recently published in Scientific Reports complicates that picture in a clinically important way.

Patients with COPD-OSAs had significantly reduced 6-minute walk distance and handgrip strength compared to those with COPD alone. Indices of sleep-disordered breathing showed significant inverse associations with both functional performance and muscle quality. In multivariable regression, oxygen desaturation index (ODI) all emerged as strongest independent predictors of muscle quality.
What this tells us clinically is that it is not just the frequency of breathing events during sleep that harms muscle. It is the depth and duration of nocturnal oxygen desaturation. Intermittent hypoxia appears to drive oxidative stress, systemic inflammation, and muscle metabolic dysfunction in a way that magnifies what COPD alone is already doing.

Sleep-disordered breathing and musculoskeletal decline are not separate conversations. In COPD, they are deeply connected.

Takeaway 1: Nocturnal hypoxia (not just apnea frequency) is the primary driver of muscle loss in patients with COPD-OSAS. Oxygen desaturation index was the strongest independent predictor of muscle quality in this study.

Takeaway 2: Handgrip strength and 6-minute walk performance were both significantly worse in patients with coexisting sleep apnea, suggesting functional decline may be partly attributable to an under-diagnosed comorbidity.

Takeaway 3: Routine screening for sleep-disordered breathing in COPD patients who show unexplained functional decline may be warranted, particularly in those with significant nocturnal desaturation.

Source: Camargo PF, et al. "Muscle Loss Worse in Individuals With COPD, Coexisting Obstructive Sleep Apnea." Scientific Reports. March 2026. Reported via HealthDay, March 19, 2026.

04/18/2026

Targeting Type 2 COPD Exacerbations with Mepolizumab in Real World Eosinophil Variability

Mepolizumab, an anti–IL-5 monoclonal antibody, was evaluated in an exploratory pooled analysis of three phase 3 trials (METREX, METREO, MATINEE) in patients with COPD and evidence of type 2 inflammation who were already on inhaled triple therapy.Across multiple eosinophilic subgroups, mepolizumab 100 mg subcutaneously consistently reduced the annualized rate of moderate or severe exacerbations compared with placebo, while patients without type 2 inflammation derived no meaningful benefit.

Patients with BEC ≥300 cells/µL at screening and baseline (Subgroup 1), mepolizumab reduced exacerbations from 1.31 to 0.95 events/year. Those with persistently high eosinophils (Subgroup 2) experienced a smaller, non‑significant 12% reduction, whereas patients with high screening BEC but lower baseline BEC (Subgroup 3) had a 22% relative risk reduction. A subgroup characterized by marked BEC variability, with values ≥300 cells/µL at any time but at least one measurement

04/17/2026

Surfactant for Infant Bronchiolitis? The Evidence Is In

A promising treatment just failed its most rigorous clinical test.

Bronchiolitis is the most common cause of infant hospital admission in high-income countries and a leading cause of infant death globally. The physiological case for surfactant therapy has always been compelling. Infants are in respiratory failure, surfactant improves surface tension, and earlier smaller trials had shown a benefit signal. It was a reasonable hypothesis.

Randomized, blinded, sham-controlled phase 2 study enrolled 232 infants across 15 pediatric ICUs in England, Scotland, and Northern Ireland. Infants requiring invasive mechanical ventilation received either endotracheal poractant alfa or a sham intervention. Duration of invasive mechanical ventilation showed no difference: 64.9 hours in the surfactant group versus 62 hours in the sham group. Every secondary outcome followed suit.

The accompanying editorial offered a useful frame. Bronchiolitis is driven by "a complex interplay of airway inflammation, mucus plugging, epithelial injury, and distal air trapping." Correcting surface tension in isolation cannot reverse that trajectory.

This is not the first time bronchiolitis has given us this lesson. Bronchodilators, corticosteroids, hypertonic saline — each carried a mechanistic rationale, each failed to deliver clinical benefit. The consistent message is that physiological plausibility and clinical efficacy are not the same thing.

SOURCE: Semple MG, et al. "Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial." Lancet Respiratory Medicine. 2026. DOI: 10.1016/S2213-2600(26)00008-1. Secondary: Kotecha S. "Surfactant therapy in severe infant bronchiolitis: evidence from the BESS trial." Lancet Respiratory Medicine. 2026. DOI: 10.1016/S2213-2600(26)00043-3.

04/17/2026

If Respiratory Therapists Are Seen As Optional In A Shaky 2026 What Happens To Patient Care When The Cuts Come

Hospitals’ 2026 financials are already under pressure, and that should fundamentally change how we think about the respiratory therapy workforce. Bad debt and charity care jumped 8% in January while volumes fell and total expenses – especially labor, supplies, and drugs – continued to climb, creating the perfect storm for hiring freezes and workforce reductions.

First, this is exactly where value-based care needs respiratory therapy at the table, not on the chopping block. When hospitals are squeezed by rising uncompensated care and cuts to Medicaid and exchange subsidies, they need RT-led programs that keep high-risk patients out of the ED and shorten length of stay, not just another round of across-the-board FTE cuts.

Second, RTs are uniquely positioned to drive “margin through outcomes.” As discharges, LOS, and ED visits decline, organizations will be forced to get more clinical and financial yield out of each encounter. Respiratory-led pathways for chronic lung disease, readmission reduction, and ventilator liberation directly support value-based contracts by improving quality while protecting revenue in an environment of shrinking payer mix.

Third, this environment demands that RT leaders start talking like population health and finance leaders. When labor costs are up 5% year over year and executives are deciding where to “be strategic” with limited resources, the RT story has to be framed in avoided admissions, reduced uncompensated care, and contract performance – not just staffing ratios and procedure volumes. In 2026’s shaky start, value-based care isn’t a buzzword for RT; it is the survival strategy.

Source: Emily Olsen, “Hospitals’ financial performance off to a shaky start in 2026,” Healthcare Dive, March 20, 2026.

04/15/2026

ARDS Precision Medicine Just Got Closer to the Bedside

A bedside blood test now separates ARDS patients with 51% mortality from those with 28%.

For years, classifying ARDS subphenotypes — hyperinflammatory versus hypoinflammatory — existed only in retrospective data. It was a research construct. Clinicians at the bedside had no practical way to stratify patients in real time, which meant precision medicine in ARDS remained a concept without a clinical pathway.

The PHIND study, published in Lancet Respiratory Medicine in March 2026 and presented at the SCCM annual meeting, changes that.
In this prospective cohort study, 512 adults with ARDS or acute hypoxemic respiratory failure from 30 ICUs across the UK and Ireland were enrolled within 72 hours of onset. Using a rapid assay measuring IL-6, soluble TNFR1, and arterial bicarbonate, researchers classified patients using a logistic regression model with an AUC of 0.94.

The mortality separation was stark. Sixty-day mortality was 51% in the hyperinflammatory group versus 28% in the hypoinflammatory group — a risk ratio of 1.8. After adjustment, hyperinflammatory patients faced 2.7 times greater odds of 60-day death.

The hyperinflammatory patients had more sepsis, more organ failure, higher APACHE II and SOFA scores, and far greater use of renal replacement therapy — despite similar lung injury severity scores. This isn't a modest difference in inflammatory state; it's a fundamentally different clinical trajectory that a three-marker bedside test can now identify in real time.

What PHIND removes is the technical barrier that constrained progress. The next step — designing treatment trials around subphenotype — is no longer theoretical.

Recognizing the subtype early could reshape escalation decisions at the bedside.

Source: Reddy K, et al. "Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study." Lancet Respir Med. 2026; DOI: 10.1016/S2213-2600(26)00040-8.

04/13/2026

You became a respiratory therapist to help people breathe. But in a value-based world, that's no longer enough — you have to prove it. Not because your work isn't valuable, but because invisible value doesn't get funded.

Respiratory therapists have spent decades proving their worth one treatment at a time. But the rules of healthcare have changed. Value-based care doesn't reward effort — it rewards evidence.

Respiratory therapy is at an inflection point. Fee-for-service rewarded volume. Value-based care rewards outcomes — and right now, most of those outcomes are attributed to everyone but us. This is a guide for RT leaders ready to own their data, define their metrics, and take a permanent seat at the value-based care table. The profession's future depends on it.

http://tiny.cc/VBCnRT

04/11/2026

When the Evidence Shifts Under Your Feet

The survival benefit we assumed for high-flow oxygen was never real.

That's the core finding of the SOHO trial, published in the New England Journal of Medicine in March 2026. In 1,116 patients across 42 ICUs in France, 28-day mortality was identical between high-flow and standard oxygen groups — 14.6% in both arms. The mortality advantage that had quietly anchored our confidence in high-flow therapy since the 2015 FLORALI trial was not replicated.

But the story doesn't end there.

High-flow oxygen still reduced intubation rates — 42.4% versus 48.4% with standard oxygen — and patients showed early improvements in respiratory rate and dyspnea consistent with reduced work of breathing and dead-space washout. Avoiding invasive ventilation matters. It matters for patient comfort, for functional recovery, and for healthcare costs.

The accompanying editorial said it plainly: this trial recalibrates expectations. It doesn't retire high-flow oxygen — it refines where it belongs. The rationale for early use in appropriate patients still holds. What changes is the certainty we bring to the bedside, and the vigilance we maintain when patients are not improving.

This is what evidence-based practice actually looks like. Not abandoning a tool when data shifts, but understanding it with more precision.

Takeaway 1 — Mortality parity does not mean clinical irrelevance.

Takeaway 2 — Physiologic rationale holds.

Takeaway 3 — Vigilance cannot be relaxed.

Source: Frat J-P, et al. "High-flow or standard oxygen in acute hypoxemic respiratory failure." N Engl J Med. 2026; DOI: 10.1056/NEJMoa2516087. Neto AS. "Rethinking high-flow oxygen in acute hypoxemic respiratory failure." N Engl J Med. 2026; DOI: 10.1056/NEJMe2602037.

04/10/2026

HFNC or CPAP for Preterm Infants? Efficacy Matches, Comfort Wins.

HFNC cut nasal injury risk by 60% compared to CPAP — with equivalent BPD outcomes.

In neonatal respiratory care, the choice between high-flow nasal cannula and CPAP has been an ongoing clinical conversation. Both are established tools for supporting preterm infants at risk for bronchopulmonary dysplasia. The tradeoffs — efficacy, tolerability, and complication burden — have been harder to quantify until now.

A systematic review and meta-analysis published in Respiratory Medicine in March 2026 draws on 20 randomized controlled trials involving 2,871 preterm infants to offer the most comprehensive head-to-head comparison to date.
The primary finding on BPD was equivalence. HFNC and CPAP showed no statistically significant difference in BPD rates in either primary support or post-extubation subgroup analyses. That is not a null finding — equivalence between two evidence-based modalities matters clinically, particularly when one carries fewer secondary complications.

That complication difference is where HFNC separated itself. Nasal injury risk was reduced by 60% with HFNC— rated as high-certainty evidence. For premature infants with fragile skin and prolonged NICU stays, nasal injury is not a minor endpoint. It affects comfort, feeding tolerance, skin integrity, and the ability to maintain effective respiratory support over time.

For NICUs navigating this choice, the data supports HFNC as a valid, effective alternative to CPAP — with a meaningfully better skin and comfort profile.

* Definitional heterogeneity in BPD criteria limits the certainty of BPD-specific evidence across studies. Standardized neonatal outcome definitions would significantly strengthen future comparative evidence.

Source: "HFNC Shows Comparable Efficacy to CPAP for BPD Prevention in Preterm Infants." Respiratory Medicine. As reported in Pulmonology Advisor, March 6, 2026.

RespiratoryRecon

04/27/2026

04/27/2026

04/25/2026

04/24/2026

04/18/2026

04/17/2026

04/17/2026

04/15/2026

04/13/2026

04/11/2026

04/10/2026

Address

Opening Hours

Website

Alerts

Contact The Practice

Shortcuts

Featured

Share

Category

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm